Compare · TIVC vs TMDX
TIVC vs TMDX
Side-by-side comparison of Tivic Health Systems Inc. (TIVC) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TIVC and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.52B, about 625.4x TIVC ($4.0M).
- Over the past year, TIVC is down 63.6% and TMDX is down 49.0% - TMDX leads by 14.6 points.
- TMDX has been more active in the news (12 items in the past 4 weeks vs 4 for TIVC).
- TMDX has more recent analyst coverage (18 ratings vs 0 for TIVC).
- Company
- Tivic Health Systems Inc.
- TransMedics Group Inc.
- Price
- $1.40+4.49%
- $72.87-1.11%
- Market cap
- $4.0M
- $2.52B
- 1M return
- +39.50%
- +13.59%
- 1Y return
- -63.58%
- -48.99%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 4
- 12
- Recent ratings
- 0
- 18
Tivic Health Systems Inc.
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. The company's primary product, ClearUP, is a medical device intended to relieve sinus and nasal inflammation. It sells its products on direct-to-consumer channel through its own websites and platforms, such as Amazon.com, as well as to major U.S. online retailers, such as BestBuy.com, FSAStore.com, Walgreens.com, Walmart.com. The company was incorporated in 2016 and is headquartered in Newark, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest TIVC
- SEC Form S-8 filed by Tivic Health Systems Inc.
- SEC Form S-8 filed by Tivic Health Systems Inc.
- Tivic Health Systems Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Chief Executive Officer Handley Michael K converted options into 2,206 shares, increasing direct ownership by 25% to 11,030 units (SEC Form 4)
- SEC Form 10-Q filed by Tivic Health Systems Inc.
- Tivic Health Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by General Counsel & SVP of Legal Lackey Melinda
- SEC Form 3 filed by new insider Lackey Melinda
- Tivic Health Systems Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form DEF 14A filed by Tivic Health Systems Inc.
Latest TMDX
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)
- Director Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)
- Director Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)
- Officer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)
- SEC Form 8-K filed by TransMedics Group Inc.